Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.

g4banpc02-845.jpg g4banph02-552.jpg

0041.png 0042.png

Our commitment to patientsResearch and develop first in class or best in class gene therapy to patients, to cure patient.Run clinical trials by following ICH guidelines and local countries’ guidelines and requirements.

Provide patients safety, efficacy, and high quality gene drug.

Patient right and witness is our first priority.

Clinical TrialsAny investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy.

Ongoing clinical trials

Peiquan Zhao
Principal Investigator
“An exploratory clinical study to evaluate the safety and tolerability of gene therapy for RPE65 mutation in Leber's congenital amaurosis type 2 (LCA2).”
Research Center
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Learn More

Patient Contact


Ongoing clinical trials

Peiquan Zhao

Dr. Zhao Peiquan MD, PHD, Professor II, Chief Physician, Doctoral Supervisor, Member of the International Ophthalmology Union Diabetic Eye Disease Prevention Task Force, Council Member of the Asia Pacific Vitreoretinal Association, Standing Member of the Chinese Medical Association Ophthalmology Branch, Vice Chairman of the Chinese Medical Association Shanghai Branch Ophthalmology Society, Member of the Chinese Medical Association Ophthalmology Branch, Fundus Disease Group, Member of the Chinese Medical Association Ophthalmologist Branch, etc.

He specializes in the diagnosis and treatment of vitreoretinal diseases in pediatric and adult patients. He was the first to develop the prevention and treatment of retinopathy of prematurity in China and established the first training center for retinopathy of prematurity screening in China. He has published more than 200 academic papers in important academic journals at home and abroad, including nearly 110 SCI-indexed papers, and has undertaken many national and provincial level projects. He has been selected as one of the leading talents in Shanghai, one of the new 100 talents in Shanghai Health Bureau, and an excellent academic leader in Shanghai Science and Technology Commission. He was awarded the second prize of China Science and Technology Progress Award, the second prize of Shanghai Medical Science and Technology Award, the third prize of Huaxia Medical Science and Technology Award, etc. In 2016, he was awarded the Distinguished Service Award of Asia-Pacific Association of Ophthalmology (APAO). he was awarded the 2019 Outstanding Communist Party Member of Shanghai Education and Health Work Party Committee System, Shanghai Charity Foundation " Charity Star", Shanghai Medical Artisan and "Good Doctor of China" in 2018.